# Eli Lilly (LLY) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/LLY
## Company Profile
- Ticker: LLY
- Exchange: NYSE
- Sector: Biopharma, mRNA Vaccines, Vaccines, Oncology, Small Molecule Drugs
- Location: United States
- Tags: Vaccines, mRNA Vaccines, Small Molecule Drugs, Oncology, Immunology
## Stock Data
- Close: 1191.94 USD
- Market cap: 948946617194.9 USD
- Last updated: 2026-08-06
## Business Overview
Eli Lilly is a large-cap pharmaceutical company with major exposure to obesity, diabetes, neuroscience, and immunology. The company has become one of the market’s clearest growth stories thanks to its metabolic franchise and broad pipeline.
## Why The Stock Is Moving

As of Aug 6, 2026, LLY closed up 1.89% at $1191.94. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NYSE, Lilly is a global pharma company with a strong commercial presence across major markets. Its investor identity is built around growth, execution, and blockbuster product momentum.

## Business Model

Lilly combines blockbuster product revenue with a deep late-stage pipeline and major manufacturing investment. Investors watch demand, supply expansion, pipeline progress, and whether the company can keep scaling its metabolic and specialty franchises.

## Landscape Position

Lilly sits at the top tier of large-cap healthcare because it has both scale and strong growth visibility. Compared with smaller biotech names, the stock is less binary but still highly sensitive to launch execution and pipeline durability.

## Future Catalysts

- Eli Lilly’s next catalysts are still centered on orforglipron, obesity and diabetes filing progress, and retatrutide development and manufacturing readiness. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.

## Recent News
- 2020-09-22 13:29 EST — [TRULICITY® (dulaglutide) est indiqué comme traitement d’appoint à un régime alimentaire, à l’exercice et au traitement standard pour réduire le risque d’accident vasculaire cérébral non mortel chez les adultes atteints de diabète de type 2 qui présentent des facteurs de risque cardiovasculaires multiples ou une maladie cardiovasculaire établie](https://biopharmsignal.com/news/LLY/trulicity-dulaglutide-est-indiqu-comme-traitement-d-appoint-un-r-gime-alimentair-6313f801) — Source: Eli Lilly and Company
- 2020-09-22 13:29 EST — [Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease](https://biopharmsignal.com/news/LLY/trulicity-dulaglutide-is-now-indicated-as-an-adjunct-to-diet-exercise-and-standa-c1ca22af) — Source: Eli Lilly and Company
- 2020-09-17 17:41 EST — [Le baricitinib en association avec le remdésivir réduit le temps de guérison chez les patients hospitalisés atteints de la COVID-19 et participant à l’étude ACTT-2 commanditée par le NIAID](https://biopharmsignal.com/news/LLY/le-baricitinib-en-association-avec-le-remd-sivir-r-duit-le-temps-de-gu-rison-che-f35895c5) — Source: Eli Lilly and Company
- 2020-09-17 17:41 EST — [Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial](https://biopharmsignal.com/news/LLY/baricitinib-in-combination-with-remdesivir-reduces-time-to-recovery-in-hospitali-e34d4ad4) — Source: Eli Lilly and Company
- 2020-09-16 20:56 EST — [Lilly dévoile des données de validation de principe concernant l’anticorps neutralisant LY-CoV555 pour le traitement de la COVID-19 en contexte ambulatoire](https://biopharmsignal.com/news/LLY/lilly-d-voile-des-donn-es-de-validation-de-principe-concernant-l-anticorps-neutr-dab5b48a) — Source: Eli Lilly and Company